Pretargeted alpha radioimmunotherapy (DOTA-PRIT) for HER2-expressing human gastric cancer: a theranostic approach using 111In/225Ac-radiohapten.
Conclusions: Alpha-DOTA-PRIT targeting the HER2 antigen, and based on Indium-111 surrogate radiohapten, achieves substantial % injected activity per gram in tumors, and is well-tolerated and effective for treatment of HER2(+) human gastric cancer mouse models, leading to CRs and significantly prolonged survival (P ≤ 0.0043 for all controls versus single-cycle anti-HER2-DOTA-PRIT). In the treated group, no deaths were observed from toxicity, and dose escalation studies continue with the goal of achieving 100% CR’s and histologic cures in preclinical models of gastric cancer.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Cheal, S., McDevitt, M., Burnes Vargas, D., Veach, D., Punzalan, B., Xu, H., Guo, H.-f., Ouerfelli, O., Cheung, N.-K., Larson, S. Tags: Basic Oncology & amp; Translational II Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Nuclear Medicine | Statistics | Students | Study | Toxicology | Universities & Medical Training | Urology & Nephrology | Weight Loss